A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients

Olanzapine has exhibited efficacy as an antiemetic agent when used with 5-HT(3) receptor antagonists, dexamethasone, and NK(1) receptor antagonists for patients receiving highly emetogenic chemotherapy. In addition, several studies have reported the efficacy or safety of olanzapine in patients recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Junichi, Hasegawa, Akiko, Kudo, Toshihiro, Otsuka, Tomoyuki, Yasui, Masayoshi, Matsuda, Chu, Haraguchi, Naotsugu, Ushigome, Hajime, Nakai, Nozomu, Abe, Tomoki, Hara, Hisashi, Shinno, Naoki, Asukai, Kei, Hasegawa, Shinichiro, Yamada, Daisaku, Sugimura, Keijiro, Yamamoto, Kazuyoshi, Wada, Hiroshi, Takahashi, Hidenori, Omori, Takeshi, Miyata, Hiroshi, Ohue, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907185/
https://www.ncbi.nlm.nih.gov/pubmed/33633328
http://dx.doi.org/10.1038/s41598-021-84225-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907185/
https://www.ncbi.nlm.nih.gov/pubmed/33633328
http://dx.doi.org/10.1038/s41598-021-84225-6

Ejemplares similares